Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now?
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
C. Chee (Singapore, Singapore). Eligibility for WHO shorter MDR treatment regimen among foreign-born MDR PTB patients in Singapore. 4854

Member's Comments

No comment yet.

Related content which might interest you: Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico Source: Eur Respir J, 51 (3) 1702267; 10.1183/13993003.02267-2017 Year: 2018 The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: are patients from South-East Asia eligible? Source: Eur Respir J, 50 (2) 1700753; 10.1183/13993003.00753-2017 Year: 2017 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Surgical treatment for MDR TB patients – preliminary results from a Romanian MDR TB centre Source: Eur Respir J 2006; 28: Suppl. 50, 276s Year: 2006 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Outcomes of individualized treatment for MDR TB in Iran Source: Annual Congress 2007 - Medical and surgical treatment of susceptible and resistant tuberculosis Year: 2007 Prevalence of MDR and XDR tuberculosis among patients with failure of re-treatment course Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Linezolid in the treatment of patients with MDR TB and XDR TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Effectiveness of treatment for MDR TB in children and adolescents Source: Annual Congress 2007 - Specific problems in caring for multidrug-resistant tuberculosis and tuberculosis/HIV cases Year: 2007 A multicentric cohort analysis of culture conversion and reversion in multidrug resistant tuberculosis (MDRTB) patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013 Frequency of risk factors for multi-drug resistant tuberculosis among the patients enrolled at multi-drug resistant clinic in a tertiary care hospital, Pakistan Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014 Treatment results for MDR TB patients after surgery Source: Eur Respir J 2005; 26: Suppl. 49, 654s Year: 2005 Safety and efficacy of supervised chemotherapy in Indian patients having multi-drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 MDR TB treatment in prison Source: Eur Respir J 2002; 20: Suppl. 38, 614s Year: 2002 Bedaquiline in the treatment of multidrug-resistant tuberculosis: a subanalysis in Korean population Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Efficacy of treatment in MDR and XDR lung TB patients in the follow-up period with the use of new anti-tuberculosis agent Source: International Congress 2019 – Extra-pulmonary tuberculosis and comorbidities Year: 2019 Concurrent use of bedaquiline and delamanid for the treatment of fluoroquinolone-resistant multidrug-resistant tuberculosis: a nationwide cohort study in South Korea Source: Eur Respir J, 57 (3) 2003026; 10.1183/13993003.03026-2020 Year: 2021 Multidrug-resistance tuberculosis and HIV-infected patients, the effectiveness of the treatment in Ukraine Source: Annual Congress 2010 - Tuberculosis drug resistance Year: 2010